Company / Operating Cash Flow
Dianthus Therapeutics, Inc. /DE/ Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$129.1M
FY2025
5-year range
-$129.1M / -$29.1M
FY2021-FY2025
Trend
-250.1%
vs FY2024
Sector context
#137 of 216
Health Care
What the data says
Operating Cash Flow changed -250% YoY in FY2025, a notable deviation from the 9-year average annual change of -66%.
Based on SEC 10-K filings.
-$129M in FY2025.
Declined from -$37M to -$129M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#137 of 216 in Health CareTop 63% of 216This company -$129.1M Sector average $659.0M
▼
-119.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 250.1% year-over-year.
- Ranks #137 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$129.1M | -250.1% |
| FY2024 | -$36.9M | +0.0% |
| FY2023 | -$36.9M | -26.8% |
| FY2022 | -$29.1M | +51.2% |
| FY2021 | -$59.5M | +7.0% |
| FY2020 | -$64.0M | -12.1% |
| FY2019 | -$57.1M | -36.3% |
| FY2018 | -$41.9M | -88.1% |
| FY2017 | -$22.3M | -241.0% |
| FY2016 | -$6.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026